Major Depressive Disorder Clinical Trial
Official title:
Effects of Electroacupuncture With Different Frequencies for Major Depressive Disorder
Verified date | January 2023 |
Source | Zhejiang Chinese Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Two groups of subjects will be included 55 subjects in electroacupuncture with 2Hz group, 55 subjects in the electroacupuncture with 100Hz group. The clinical efficacy of electroacupuncture with different frequencies (2 Hz, 100 Hz) in the treatment of MDD will be observed by evaluation indicators, such as Self-rating depression scale and Hamilton depression scale.
Status | Active, not recruiting |
Enrollment | 110 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Patients su?ering from MDD in accordance with the diagnostic criteria; 2. Hamilton Depression Scale score is between 21 and 35 (mild to moderate MDD); 3. 18=age=60 years, both gender; 4. Patients who have not used antidepressants and other psychiatric drugs (including traditional Chinese medicine), or have used them but have stopped for at least 2 weeks; 5. Patients have clear consciousness and could communicate with others normally; 6. Patients could understand the full study protocol and written informed consent is provided by themselves. Note: Subjects who meet the above six items will be included. Exclusion Criteria: 1. Patients with bipolar disorder; 2. Patients with schizophrenia or other mental disorders; 3. Patients with severe medical diseases, tumors or diseases of the central nervous system; 4. Patients su?ering from severe depressive episode with psychotic symptoms; 5. Suicidal patients; 6. Patients with seasonal depression; 7. Patients with organic depression; 8. Patients with alcohol or drug addicts; 9. Patients using other therapies; 10. Patients in pregnancy or lactation; 11. Patients suffering from cognitive dysfunction, aphasia or other diseases that cannot cooperate with treatment; 12. Patients with pacemakers; 13. Patients who are not suitable for electroacupuncture. |
Country | Name | City | State |
---|---|---|---|
China | Xiaoyu Li | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Zhejiang Chinese Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in anxiety and depression severity measure by Self-rating depression scale(SDS) | This scale contains 20 items that reflect the subjective feelings of depression, 10 of which are positive scores and 10 are reverse scores. Each item is divided into four grades according to the frequency of symptoms, If it is a positive scoring question, it will be rated as 1, 2, 3, and 4 points; for a reverse scoring question, it will be rated as 4, 3, 2, and 1. After the evaluation, add up the scores in the 20 items to get the total rough score, and then multiply the rough score by 1.25 and take the integer part to get the standard score | There will be evaluated before intervention, at 2, 4weeks after intervention and at the end of 4-weeks follow-up. | |
Primary | Change in the severity of depression measure by Hamilton depression scale (HAMD) | This scale is performed by two trained raters to perform a HAMD, usually in the form of conversation and observation. After the examination, the two raters will score independently | There will be evaluated before intervention, at 2, 4weeks after intervention and at the end of 4-weeks follow-up. | |
Secondary | Change in sleep quality measured by Insomnia severity index (ISI) | There will be evaluated before intervention, at 2, 4weeks after intervention and at the end of 4-weeks follow-up. | ||
Secondary | Change in Traditional Chinese medicine syndrome score | There will be evaluated before intervention, at 2, 4weeks after intervention and at the end of 4-weeks follow-up. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |